These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 11320667)

  • 21. Biochemical pharmacology and resistance to 2-chloro-2'-arabino-fluoro-2'-deoxyadenosine, a novel analogue of cladribine in human leukemic cells.
    Lotfi K; Månsson E; Spasokoukotskaja T; Pettersson B; Liliemark J; Peterson C; Eriksson S; Albertioni F
    Clin Cancer Res; 1999 Sep; 5(9):2438-44. PubMed ID: 10499616
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cytidine deaminase - the methodological relevance of AraC deamination for ex vivo experiments using cultured cell lines, fresh leukemic blasts, and normal bone marrow cells.
    Braess J; Pförtner J; Kern W; Hiddemann W; Schleyer E
    Ann Hematol; 1999 Nov; 78(11):514-20. PubMed ID: 10602895
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cellular resistance against troxacitabine in human cell lines and pediatric patient acute myeloid leukemia blast cells.
    Adema AD; Zuurbier L; Floor K; Hubeek I; Kaspers GJ; Albertoni F; Peters GJ
    Nucleosides Nucleotides Nucleic Acids; 2006; 25(9-11):981-6. PubMed ID: 17065050
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Troxacitabine and imatinib mesylate combination therapy of chronic myeloid leukaemia: preclinical evaluation.
    Orsolic N; Giles FJ; Gourdeau H; Golemovic M; Beran M; Cortes J; Freireich EJ; Kantarjian H; Verstovsek S
    Br J Haematol; 2004 Mar; 124(6):727-38. PubMed ID: 15009060
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Impact of cytidine deaminase activity on intrinsic resistance to cytarabine in carcinoma cells.
    Ohta T; Hori H; Ogawa M; Miyahara M; Kawasaki H; Taniguchi N; Komada Y
    Oncol Rep; 2004 Nov; 12(5):1115-20. PubMed ID: 15492802
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Metabolism of 4'-thio-beta-D-arabinofuranosylcytosine in CEM cells.
    Parker WB; Shaddix SC; Rose LM; Waud WR; Shewach DS; Tiwari KN; Secrist JA
    Biochem Pharmacol; 2000 Dec; 60(12):1925-32. PubMed ID: 11108809
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Determinants of sensitivity of human T-cell leukemia CCRF-CEM cells to immucillin-H.
    Huang M; Wang Y; Gu J; Yang J; Noel K; Mitchell BS; Schramm VL; Graves LM
    Leuk Res; 2008 Aug; 32(8):1268-78. PubMed ID: 18279955
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cyclopentenyl cytosine induces apoptosis and increases cytarabine-induced apoptosis in a T-lymphoblastic leukemic cell-line.
    Verschuur AC; Brinkman J; Van Gennip AH; Leen R; Vet RJ; Evers LM; Voûte PA; Van Kuilenburg AB
    Leuk Res; 2001 Oct; 25(10):891-900. PubMed ID: 11532523
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Troxacitabine prodrugs for pancreatic cancer.
    Adema AD; Radi M; Daft J; Narayanasamy J; Hoebe EK; Alexander LE; Chu CK; Peters GJ
    Nucleosides Nucleotides Nucleic Acids; 2007; 26(8-9):1073-7. PubMed ID: 18058539
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effect of hypoxia on the expression of phosphoglycerate kinase and antitumor activity of troxacitabine and gemcitabine in non-small cell lung carcinoma.
    Lam W; Bussom S; Cheng YC
    Mol Cancer Ther; 2009 Feb; 8(2):415-23. PubMed ID: 19208827
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Phase II study of troxacitabine (BCH-4556) in patients with advanced and/or metastatic renal cell carcinoma: a trial of the National Cancer Institute of Canada-Clinical Trials Group.
    Townsley CA; Chi K; Ernst DS; Belanger K; Tannock I; Bjarnason GA; Stewart D; Goel R; Ruether JD; Siu LL; Jolivet J; McIntosh L; Seymour L; Moore MJ;
    J Clin Oncol; 2003 Apr; 21(8):1524-9. PubMed ID: 12697876
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Troxacitabine activity in extramedullary myeloid leukemia.
    Alvarado Y; Kantarjian HM; Cortes JE; Apostolidou E; Bivins C; Giles FJ
    Hematology; 2002 Jun; 7(3):179-85. PubMed ID: 12243982
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Phase I/II study of continuous-infusion troxacitabine in refractory acute myeloid leukemia.
    Roboz GJ; Giles FJ; Ritchie EK; Allen-Bard S; Curcio TJ; Wilkes MA; Park SL; Kantarjian HM; Faderl S; Ravandi F; Kelner MJ; Feldman EJ
    J Clin Oncol; 2007 Jan; 25(1):10-5. PubMed ID: 17146106
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A phase II multicenter study of troxacitabine in relapsed or refractory lymphoproliferative neoplasms or multiple myeloma.
    Vose JM; Panwalkar A; Belanger R; Coiffier B; Baccarani M; Gregory SA; Facon T; Fanin R; Caballero D; Ben-Yehuda D; Giles F
    Leuk Lymphoma; 2007 Jan; 48(1):39-45. PubMed ID: 17325846
    [TBL] [Abstract][Full Text] [Related]  

  • 35. In vitro optimization of non-small cell lung cancer activity with troxacitabine, L-1,3-dioxolane-cytidine, prodrugs.
    Radi M; Adema AD; Daft JR; Cho JH; Hoebe EK; Alexander LE; Peters GJ; Chu CK
    J Med Chem; 2007 May; 50(9):2249-53. PubMed ID: 17419604
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Phase I and pharmacokinetic study of novel L-nucleoside analog troxacitabine given as a 30-minute infusion every 21 days.
    Bélanger K; Moore M; Baker SD; Dionne J; Maclean M; Jolivet J; Siu L; Soulières D; Wainman N; Seymour L
    J Clin Oncol; 2002 May; 20(10):2567-74. PubMed ID: 12011137
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Long intracellular retention of 4'-thio-arabinofuranosylcytosine 5'-triphosphate as a critical factor for the anti-solid tumor activity of 4'-thio-arabinofuranosylcytosine.
    Someya H; Waud WR; Parker WB
    Cancer Chemother Pharmacol; 2006 Jun; 57(6):772-80. PubMed ID: 16180016
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Induction of cytidine deaminase in HL-60 myeloid leukemic cells by 5-aza-2'-deoxycytidine.
    Momparler RL; Laliberté J
    Leuk Res; 1990; 14(9):751-4. PubMed ID: 1700230
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Antileukemia activity of a natural killer cell line against human leukemias.
    Yan Y; Steinherz P; Klingemann HG; Dennig D; Childs BH; McGuirk J; O'Reilly RJ
    Clin Cancer Res; 1998 Nov; 4(11):2859-68. PubMed ID: 9829753
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Phase II study of troxacitabine, a novel dioxolane nucleoside analog, in patients with untreated or imatinib mesylate-resistant chronic myelogenous leukemia in blastic phase.
    Giles FJ; Feldman EJ; Roboz GJ; Larson RA; Mamus SW; Cortes JE; Verstovsek S; Faderl S; Talpaz M; Beran M; Albitar M; O'Brien SM; Kantarjian HM
    Leuk Res; 2003 Dec; 27(12):1091-6. PubMed ID: 12921945
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.